How Kelonia Therapeutics Went From Near Bankruptcy to a $3.25B Lilly Acquisition — and What It Means for Biotech M&A and Telehealth Partnerships

Eli Lilly has agreed to acquire Kelonia Therapeutics, a biotechnology company developing in vivo CAR-T cell therapies for cancer, in a deal valued at up to $7 billion. The agreement includes an upfront payment of $3.25 billion, with additional payments contingent on the achievement of clinical, regulatory, and commercial milestones. The transaction is expected to close in the second half of 2026.

Kelonia Therapeutics is focused on creating therapies that reprogram a patient’s T-cells inside the body to target and attack cancer cells. This approach, known as in vivo CAR-T, differs from current CAR-T treatments, which require extracting a patient’s immune cells, engineering them in a laboratory setting, and then reinfusing them back into the patient—a process referred to as ex vivo CAR-T. The in vivo method aims to eliminate the need for laboratory processing and preconditioning chemotherapy, potentially simplifying treatment delivery and reducing associated risks.

According to Jacob Van Naarden, president of Lilly Oncology and head of corporate business development, the therapy is designed to be administered intravenously in a single dose and does not require preconditioning. He stated that the treatment “targets your body’s T-cells, transforms them into attacking the cancer in the body, and requires no preconditioning at all.”

The acquisition underscores Eli Lilly’s strategy to expand its oncology portfolio through targeted investments in innovative cell therapies. Kelonia’s technology has attracted attention amid growing interest in next-generation immunotherapies, particularly as companies seek to overcome the logistical and clinical challenges associated with existing ex vivo CAR-T products. Current CAR-T therapies have shown success in treating certain blood cancers, such as multiple myeloma, but are often limited by complex manufacturing processes and side effect profiles.

The deal reflects broader trends in the pharmaceutical industry, where large drugmakers are acquiring smaller biotech firms to access early-stage but potentially transformative therapies. Similar moves include Gilead Sciences’ acquisition of Arcellx and its anito-cel therapy, a candidate positioned as a rival to Johnson & Johnson’s Carvykti, which generated $1.89 billion in sales last year. These transactions highlight the competitive landscape in cellular immunotherapy and the value placed on differentiated approaches like in vivo delivery.

While the upfront payment of $3.25 billion represents one of the largest acquisitions of a clinical-stage biotech in recent years, the final value of the deal depends on Kelonia meeting predefined milestones. Neither Eli Lilly nor Kelonia has disclosed specific timelines for clinical trials or regulatory submissions related to its in vivo CAR-T programs. As such, the therapeutic potential and development trajectory of the technology remain subject to future clinical data.

For patients, the promise of in vivo CAR-T lies in its potential to reduce the burden of treatment by avoiding the need for leukapheresis, laboratory manufacturing, and lymphodepleting chemotherapy. However, the approach is still investigational, and key questions remain regarding its safety, durability of response, and applicability across different cancer types. Ongoing research will be necessary to determine whether in vivo CAR-T can achieve outcomes comparable to or better than existing ex vivo therapies.

The acquisition marks a significant milestone for Kelonia Therapeutics, which had previously faced financial challenges, including reported difficulties in securing funding. Its ability to advance a novel therapeutic platform despite those constraints has now culminated in a major pharmaceutical partnership. How this acquisition influences future innovation in cell therapy—and whether similar deals will continue to shape the oncology landscape—remains an area of close industry attention.